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Abstract
Introduction: Patients with CF present numerous pathological conditions such as malnutrition, depletion of fat-free mass, metabolic 
disturbances (abnormal glucose metabolism, increased insulin resistance, chronic energy deficit, local and chronic inflammation), which 
could affect or be associated with altered adipokines concentration.
Material and methods: We aimed in this study to investigate the levels of selected adipokines such as resistin, apelin, adiponectin to 
demonstrate their application as possible markers of inflammation.
Results: Serum level of resistin was higher (p < 0.001) and adiponectin — lower (p = 0.02) in CF children than in healthy children. There 
was no difference in serum apelin level between two examined groups. However, values of adiponectin/BMI and apelin/BMI ratios in CF 
did not differ significantly from controls. Higher values of resistin/BMI ratio in CF in comparison to controls were observed Serum resistin/ 
/adiponectin ratio was significantly higher in CF patients than in controls (p < 0.0001). Resistin/BMI ratio correlated negatively with FEV1 
(R: –48, p < 0.043). Serum resistin/adiponectin ratio correlated negatively with FEV1/FVC (R: –49, p = 0.04), Adipokines showed no cor-
relation with BMI and BMI-SDS, glucose, total cholesterol, and LDL-, HDL-cholesterol, triglyceride serum levels. Spirometric parameters 
FEV1, FVC, VC correlated negatively with serum glucose levels (R: –0.55, p < 0.018; R: –0.65 p < 0.0025; R: –0.76, p < 0.0008 respectively). 
FEV1 and FVC correlated positively with BMI-SDS (R: 0.58, p < 0.01; R: 0.5, p < 0.036, respectively).
Conclusions: A significant increase in resistin concentration expressed also as resistin/BMI, and resistin/adiponectin ratios, observed in 
children with CF may suggests that this adipokine is involved in the inflammatory process underlying the disease and is related to worse 
spirometric parameters describing airways obstruction. (Endokrynol Pol 2018; 69 (2): 128–134)
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Streszczenie
Wstęp: Pacjenci z mukowiscydozą (CF) ujawniają liczne stany patologiczne, takie jak niedożywienie, zmniejszenie beztłuszczowej masy 
ciała, zaburzenia metaboliczne m.in. nieprawidłowy metabolizm glukozy, zwiększoną insulinooporność, przewlekły deficyt energetyczny, 
miejscowe i przewlekłe stany zapalne, które mogą wpływać lub być związane ze zmianami stężenia adipokin.
Materiał i metody: Celem aktualnego badania było oznaczenie stężenia wybranych adipokin, takich jak rezystyna, apelina, adiponektyna 
w celu wykazania możliwości ich zastosowania jako markerów stanu zapalnego.
Wyniki: Stężenie rezystyny w surowicy było wyższe (p < 0.001) a adiponektyny — niższe (p = 0,02) u dzieci z CF niż u zdrowych dzieci. 
Nie stwierdzono różnicy w stężeniu apeliny w surowicy krwi pomiędzy tymi dwoma badanymi grupami. Wartości wskaźników adipo-
nektyna/BMI i apelina/BMI u dzieci z CF nie różniły się jednakże znacząco od stwierdzanych w grupie kontrolnej. Obserwowano wyższe 
wartości wskaźnika rezystyna/BMI w CF w porównaniu z grupą kontrolną Wskaźnik rezystyna/adiponektyna w surowicy był znacząco 
wyższy u pacjentów z CF niż u osób z grupy kontrolnej (p < 0.0001). Stosunek rezystyna/BMI korelował negatywnie z FEV1 (R: –48, 
p < 0.043). Stosunek rezystyna/adiponektyna w surowicy korelował negatywnie z FEV1 / FVC (R: –49, p = 0,04). Stężenie adipokin 
w surowicy nie wykazało korelacji z BMI i BMI-SDS, stężeniem glukozy, cholesterolu całkowitego, stężeniem cholesterolu LDL i HDL, 
stężeniem triglicerydów. Parametry spirometryczne FEV1, FVC, VC korelowały negatywnie ze stężeniem glukozy w surowicy (R: –0,55, 
p < 0.018, R: –0,65 p < 0.0025, R: –0,76, p < 0.0008). FEV1 i FVC wykazywały dodatnią korelację z BMI-SDS (R: 0,58, p < 0,01, R: 0,5, 
p < 0.036).
Wnioski: Znaczne zwiększenie stężenia rezystyny wyrażone również jako wskaźnik rezystyna /BMI oraz stosunek rezystyna/adi-
ponektyna, obserwowane u dzieci z CF może sugerować, że ta adipokina jest zaangażowana w proces zapalny leżący u podstaw 
choroby i jest związana z pogorszeniem parametrów spirometrycznych opisujących niedrożność dróg oddechowych.(Endokrynol 
Pol 2018; 69 (2): 128–134)
Słowa kluczowe: mukowiscydoza, adipokiny, rezystyna, apelina, adiponektyna, dzieci, stan zapalny
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Introduction
Cystic fibrosis (CF) is an untreatable and life-
shortening inherited autosomal recessive disease 
with multiorgan manifestation. It is caused by dif-
ferent mutations in a single gene, localized on the 
long arm of chromosome 7 at position q31.2., which 
codes Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR). CFTR protein is a cAMP-activated 
chloride channel expressed at the apical membrane 
on the surface of epithelial cells lining the airways, 
gastrointestinal tract, cells of exocrine pancreas, air-
way submucosal and sweat glands [1]. To date, more 
than 1900 mutations of the CFTR gene have been 
identified. DF508 — deletion of phenylalanine 508 
is the most prevalent mutation, with approximately 
90% of all CF patients carrying it on at least one allele, 
and unfortunately it is associated with a severe clini-
cal phenotype. The defective or absent CFTR protein 
results in poor transport of salt and water into and out 
of the cells in number of organs. The extent of clinical 
manifestations is highly heterogeneous in distinct 
organs. Leading symptoms of typical CF include in-
creased electrolytes concentration in sweat, exocrine 
pancreatic insufficiency and progressive pulmonary 
dysfunction, which is responsible for more than 80% 
of CF-related deaths [1]. CF-associated bronchopul-
monary disease is characterized by multiply altera-
tions including mucostasis, mucus hypersecretion, 
and chronic neutrophilic inflammation with recurrent 
bacterial infections, mainly caused by Pseudomonas 
aeruginosa and Staphylococcus aureus [2, 3].
Other CF clinical manifestations comprise chronic 
rhinosinusitis, hepatic and intestinal disorders, diabetes 
mellitus, male infertility [1]. Cystic fibrosis is associated 
with malnutrition, depletion of body fat, but increased 
percentage of visceral adipose tissue [4, 5].
Adipokines are protein mediators secreted by the 
adipose tissue, which were found to be associated with 
the chronic low-grade inflammation process present 
in inflammatory diseases and chronic disturbances of 
metabolism [6–9]. With related receptors extensively 
dispersed throughout the body, including the lungs, 
adipokines may be a contributing factor underlying 
the complications of CF. 
We have planned to investigate serum levels of se-
lected adipokines such as resistin, apelin, adiponectin 
to demonstrate their application as possible markers 
of inflammation. 
Resistin is expressed in brown and white adipose 
tissue and is a member of cysteine rich proteins family, 
called resistin — like molecules (RELMs), also known 
as the FIZZ family (found in inflammatory zones). 
Circulating monocytes and macrophages seem to be 
responsible for resistin production in human. Resistin 
has proinflammatory properties and upregulates the 
expression of monocyte chemo-attractant protein-1 
(MCP-1) as well as vascular cell adhesion molecule 
— 1 (VCAM-1) and intercellular adhesion molecule 
— 1 (ICAM-1) in endothelial cells, which have been 
known to contribute in the pathogenesis of inflam-
mation [10, 11].
Adiponectin is a well-known adipokine that has 
anti-diabetic, anti-inflammatory and anti-oxidative 
effects [12]. Low serum adiponectin levels are related 
to obesity, insulin resistance, diabetes mellitus and car-
diovascular disease, and lipodystrophy [8, 9]. On the 
other hand higher adiponectin serum levels have been 
reported in patients with deficits of energy in anorexia 
nervosa and bulimia and patients with bronchiectases 
with fat-free depletion or CF [5, 8, 9]. 
Apelin (APE) is a novel bioactive peptide identified 
as the endogenous ligand of the previously discovered 
“orphan” G-protein-coupled receptor named APJ, 
isolated by Tatemoto et al. [13] from bovine stomach 
extracts in 1998. Several different isoforms of APE 
have been identified that are thought to exist in vivo. 
The predominant form of circulating APE is believed 
to be APE-36; however, shorter C-terminal fragments 
with biological activity have been found, including 
APE-17, APE-16, APE-13 and its pyroglutamylated 
form (APE-p[Glu]-13), and APE-12 [14, 15]. It has been 
demonstrated that the biological activity of APEs is 
related inversely to the peptide length; thus, APE-
12 is the most potent isoform. APE belongs to the 
adipokines group because its mRNA expression has 
been demonstrated in mature adipocytes and vascular 
stroma of fat tissue in rodents and humans as well as 
in murine preadipocyte cell lines (3T3F442A) [16, 17]. 
APE peptide expression has been also detected in CNS 
neuronal cells (APE-p[Glu]-13 and APE-17), placenta, 
breast in pregnant and lactating women (APE-36 and 
APE-p[Glu]-13), pancreas, kidneys, prostate, testes 
(APE-36), uterus (APE-36), gastrointestinal tract, and 
osteoblasts [18, 19].
This multifunctional apelinergic system is also 
highly expressed in pulmonary tissue. APJ is expressed 
in bronchial and alveolar epithelial cells, in small pul-
monary blood vessels in the endothelium and in the 
smooth muscle cells [20]. 
Only a few reports conducted in adult patients with 
CF focus on the pro-inflammatory role of leptin and 
anti-inflammatory of adiponectin, which potentially 
may affect inflammation and glucose tolerance as well 
as nutritional status in this group [5, 21, 22]. However, 
recent human data are inconclusive regarding the 
independent association between serum leptin or se-
rum adiponectin and CF symptoms severity in adults. 
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The potential association between CF and resistin and 
apelin has not been explored in CF so far and remains 
obscure.
We hypothesized, that resistin, apelin and adi-
ponectin also participate in CF pathophysiology and 
are associated with the severity of CF clinical features. 
Material and methods
The study group comprised 21 children (aged 4.5–18 
years; mean age 11.34 ± 0.37 years) with stable CF. The 
diagnosis of CF was established by sweat test and later 
confirmed by genetic tests in all subjects. All patients 
were treated according to European and U.S. guide-
lines [24]. Patients with pulmonary exacerbation were 
excluded from this study. In all children the following 
parameters were assessed: patient history and physical 
examination, anthropometric parameters, sputum and 
blood samples, and lung function tests.
The control group consisted of 22 healthy children 
(aged 4–17 years; mean age 10.9 ± 4.4years). Children 
from the control group attended the outpatient pedia-
tric clinic for non-immunological, non-inflammatory 
health problems and needed venous puncture.
The present study was approved by Ethics Commit-
tee of the Medical University of Silesia in Katowice and 
written informed consent was obtained from children’s 
parents.
Laboratory assays
Blood samples for assays were collected in the fasting 
state between 8–930 am. After centrifugation at 1000 × 
g for 15 min at 4°C, the serum samples were frozen at 
–20°C until analyzed. The absorbance measurements 
for all samples were performed using the Quant Uni-
versal Microplate Spectrophotometer (BioTek Instru-
ments Inc., Winooski, VT) determined on the basis of 
the standard curve made for a series of dilutions of 
the standards available in the kit. Acquired data were 
analyzed using KCJunior Software (v.1.31.5, Bio-Tek 
Instruments,Winooski, VT, USA).
Serum resistin concentration was measured by 
commercially available enzyme-linked immunosorb-
ent assay kit (Mediagnost, Reutlingen, Germany) as 
described in our previous study [24] . The concentra-
tion of resistin was determined on the basis of standard 
curve carried out for serial dilution available in kit 
standards (human recombinant resistin). Immuno-
complex detection was determined on the basis of 
reaction with rabbit polyclonal antibody antihuman 
immunoglobulin (IgG) conjugated with horseradish 
peroxides and then with TMB substrate solution (TMB 
substrate, slow kinetic, Sigma-Aldrich, St. Louis, MO, 
USA). The sensitivity for resistin was 0.012 ng/mL, and 
the intra- and interassay CV was 4.66% and 4.79%, 
respectively. 
Serum apelin-12 concentration was determined us-
ing commercial human Apelin-12 enzyme immunoas-
say kit (Phoenix Pharmaceuticals Inc., Burlingame, CA) 
following the manufacturer’s instructions as described 
in our previous study [25]. Serum samples were extract-
ed before the assay, to isolate analyzed peptides. Buffer 
A (1% trifluoroacetic acid aqueous solution), buffer B 
(60% acetonitrile solution in 1% trifluoroacetic acid 
solution), and SEP-PAK C chromatographic columns 
(Waters Associates, Milford, MA) were used for extrac-
tion. Before the analysis, after lyophilisation, obtained 
extract was dissolved in the assay buffer.
The sensitivity was 0.07 ng/mL for Apelin-12 kit; the 
intraassay coefficient of variance (CV) was 5% or less, 
and the extraassay CV was 14%.
Serum adiponectin concentration was measured by 
commercially available enzyme-linked immunosorbent 
assay kit (Bio-Vendor, LLC, USA). The procedure was 
done according to manufacturer ’s instruction. The 
sensitivity for adiponectin was 0.7 ng/mL, and the in-
tra- and interassay CV was 7.0% and 8.2%, respectively.
All statistical analyses were performed using (Med-
Calc ver. 12.4.0.0) and p values of < 0.05 were consid-
ered to be significant. To compare the characteristics of 
the subgroups the Mann-Whitney U-test was applied. 
Correlations were analyzed with Spearman tests. 
Besides absolute values of examined adipokines con-
centration in serum we additionally expressed results 
in relation to BMI as apelin/BMI, adiponectin/BMI and 
resistin/BMI ratios.
Results
The characteristics of 20 children with CF and 22 healthy 
control subjects is presented in Table I. Mean values 
of BMI in CF group were significantly lower than in 
control group.
The mean values of serum levels of adiponectin, 
apelin, resistin in all children are shown in Table II. 
Serum levels of resistin were significantly higher and 
adiponectin significantly lower in CF children than in 
healthy children (p = 0.001 for resistin, p = 0.001 for 
adiponectin). There was no difference in serum apelin 
levels between two examined groups. However, values 
of adiponectin/BMI ratios and apelin/BMI ratios in CF 
did not differ significantly from controls, but still were 
observed significantly higher values of resistin/BMI 
ratios in CF in comparison to controls. Serum resistin/
adiponectin ratio was significantly higher in CF patients 
than in controls (p < 0.0001) (Fig. 1).
We have documented few correlations between 
adipokine levels and other parameters. Age of CF 
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Table I. Characteristics of examined children
Tabela I. Charakterystyka badanych grup dzieci
Characteristics Children with CF(n = 21) Healthy Children (n = 22) P
Age [years]
Sex [n]
Height [cm]
Weight [kg]
BMI [kg/m2]
BMI-SDS
11.7 ± 1.6
F:11; M:10
144 ± 9.84
36.8 ± 15.7
17.1 ± 1.4
–0.58 ± –0.71
10.9 ± 4.4
F:12; M:10
144.9 ± 21.7
39.5 ± 13.0
18.3 ± 0.98
0.95 ± 0.82
ns
ns
0.02
0.03
0.01
CRP [mg/dL]
WBC
Fasting Glucose [mgdL]
TC [mmol/L]
LDL cholesterol [mmol/L
HDL cholesterol [mmol/L
TG [mmol/L]
AspAT [IU/mL]
AlAT [IU/mL]
3.43 ± 1.77
8.9 ± 1.42
94.43 ± 4.12
3.42 ± 0.36
1.76 ± 0.26
1.2 ± 0.12
1.08 ± 0.23
32 ± 0.8
33.5 ± 72
0.54 ± 0.17
6.63 ± 0.85
84.36 ± 2.67
3.14 ± 0.28
1.79 ± 0.41
1.27 ± 0.28
1.26 ± 0.77
 25.41 ± 4.16
15.88 ± 3.02
0.05
0.01
0.003
ns
ns
ns
ns
ns
0.001
FEV1 [% predicted]
FVC [% predicted]
FEV1/FVC [%]
65.62 ± 9.73
67.11 ± 8.6
78.87 ± 6.28
95.82 ± 1.7
94.11 ± 2.8
90.03 ± 1.5
0.0001
0.0001
0.0001
Data are shown as mean ± 1,96*SEM 
BMI — body mass index; BMI-SDS —body mass index standard deviation scores; CRP — C-reactive protein;, HDL-C — high-density lipoprotein cholesterol; IU — 
international unit; LDL-C — low-density lipoprotein cholesterol; SE — standard error; TC — total cholesterol; TG — triglyceride; FEV1 — forced expiratory volume in 1 
second; FVC — forced vital capacity
Table II. Mean values of adipokine serum levels in children with cystic fibrosis and healthy children
Tabela II. Średnie wartości stężeń adipokin w surowicy krwi u dzieci z mukowiscydozą i u dzieci zdrowych
Adipokines CF Healthy subjects P value
Adiponectin [µg/mL]
Adiponectin /BMI
13.6 ± 0.69
0.82 ± 0.06
14.98 ± 0.94
0.84 ± 0.06
0.02
0.6
Apelin [pg/mL]
Apelin pg/BMI
82.9 ± 4.53
4.97 ± 0.38
81.4 ± 4.95
4.53 ± 0.31
0.6
0.1
Resistin [ng/mL]
Resistin /BMI
8.7 ± 0.3
0.53 ± 0.03
5.6 ± 0.44
0.31 ± 0.03
 < 0.001
 < 0.001
Resistin [ng/mL] /adiponectin x10-3 0.66 ± 0.55 0.38 ± 0.04  < 0.0001
Data are shown as mean ± 1.96*SEM
patients correlated positively with CRP and resistin 
levels (R: 0.7, p < 0.0006; R: 0.49, p < 0.021, respec-
tively) and negatively with adiponectin serum levels 
(R:–0.51, p < 0.01) and BMI-SDS (R –0.55, p < 0.0096). 
BMI of CF children correlated with BMI-SDS (R:0.6, 
p < 0.0018), TG (R: 0.8, p < 0.0001) and CRP levels (R: 0.52, 
p < 0.0017). CRP correlated with resistin levels (R: 0.58, 
p < 0.0064), TG levels (R: 0.65, p < 0.0044), BMI (R:0.52, 
p < 0.018). Spirometric parameters FEV1 and FVC and 
VC correlated negatively with serum glucose levels 
(R: –0.55, p < 0.018; R: –0.65 p < 0.0041; R: –0.76, 
p < 0.0008 respectively). FEV1 and FVC correlated 
positively with BMI-SDS (R:0.58, p < 0.01; R: 0.5, 
p < 0.036, respectively). Resistin/BMI correlated negative-
ly with FEV1 (R: –0.48, p < 0.043) (Fig. 2). Serum resistin/
adiponectin ratio correlated negatively with FEV1/FVC 
(R: –0.49, p = 0.04) (Fig. 3). Adiponectin and apelin 
showed no correlation with BMI and BMI-SDS, glucose, 
total cholesterol and LDL-, HDL-cholesterol, triglycer-
ide serum levels and spirometric parameters.
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Discussion
CF patients present numerous pathological conditions 
such as malnutrition and depletion of fat free mass, 
metabolic disturbances including abnormal glucose me-
tabolism, increased insulin resistance, chronic energy 
deficit, local and chronic inflammation, all of which 
could affect or be associated with altered adipokines 
concentration [1, 2–4]. 
The results obtained in the current study showed 
that there was significant increase of resistin, concen-
trations in CF children in comparison with healthy 
controls. The role of resistin in patients with CF has not 
yet been investigated, so to our best knowledge is the 
first report showing this pro-inflammatory adipokine 
increase in CF children. 
Macrophage exposure to resistin has been shown 
to induce expression of tumor necrosis factor alpha 
(TNF-alpha) and IL-12, IL-6. Furthermore, in human 
epithelial cells, RELMb induced increased proliferation, 
mucin and growth factor production, suggesting a po-
tential contribution to airway remodeling. Interestingly 
adiponectin inhibits some effect of resistin [8, 26, 27]. 
Increasing evidence indicates that resistin plays an im-
portant regulatory role in insulin resistance, and several 
pathological processes including asthma, cardiovascular 
disease, and inflammatory bowel disease [7, 24, 26–28]. 
In patients with asthma and chronic obstructive pul-
monary disease resistin correlated negatively wit FEV1 
[26–28]. In our previous study resistin/BMI ratio cor-
related inversely with FVC of asthmatic children [24]. 
In several pathophysiological conditions, plasma resis-
tin concentrations have been associated with circulat-
ing pro-inflammatory mediators, including CRP [28]. 
In our study resistin levels correlated positively with 
CRP, which is a commonly recognized acute phase 
protein. Recently Ballantyne et al. [27] suggested that 
balance between resistin and adiponectin is important 
in asthma pathology and resistin/adiponectin ratio is 
a positive predictor of FEV1 and is higher in asthmatics 
who have more severe disease. In our present study 
we also observed higher resistin/ adiponectin ratio in 
CF compared to controls, which indicate the relative 
excess of proinflammatory adipokine resistin and rela-
tive deficit antinflammatory adipokine — adiponectin. 
Moreover resistin/adiponectin ratio in CF inversely 
correlated with FEV1/FVC.
Figure 1. Comparision resistin/adiponectin ratio between CF 
patient and healthy and control group
Rycina 1. Porównanie wskaźnika rezystyna/adiponektyna u dzieci 
z mukowiscydozą i u dzieci zdrowych
Figure 2. Correlation between resistin/BMI ratio and FEV1
Rycina 2. Analiza korelacji pomiędzy wskaźnikiem rezystyna/ 
/BMI i FEV1
Figure 3. Corelation between resisin/adiponectin ratio in CF 
and FEV1/FVC
Rycina 3. Analiza korelacji pomiędzy wskaźnikiem rezystyna/ 
/adiponektyna i FEV1/FVC u dzieci z mukowiscydozą
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Resistin is also implicated in the development 
of atherosclerosis, by affecting the course of chronic 
inflammatory response and cell proliferation and dif-
ferentiation. [35]. In our study, however we have not 
found relationship of adipokines with lipid metabolism 
parameters. The study evaluating the risk of atheroscle-
rosis in patients with CF, which purpose is to examine 
CF patients in relation to the exogenous and endog-
enous factors that influence the course of the disease 
will put a new light on this topic [36]. 
In our study serum adiponectin was significantly 
lower in CF group than in control group, but adipo-
nectin /BMI ratio did not differ from healthy children. 
Adiponectin is primarily considered to be anti-inflam-
matory due to its dual role in inhibiting the effects of 
pro-inflammatory cytokines (e.g. TNF alfa induced IL-
18, IL-6) and inducing expression of anti-inflammatory 
cytokines (e.g. IL-10 and IL1RA) [6, 7]. In low levels 
may be partially responsible for excessive inflammatory 
response which plays a key role in chronic bacterial in-
fection and pulmonary exacerbation and lung function 
decline in CF patients. 
One of the major characteristic symptoms of CF air-
ways is chronic inflammation. The CF airways contain 
several proinflammatory mediators including TNF-alfa, 
IL-1 beta, IL-6, IL-8, MIF [2, 3]. It has been suggested that 
adiponectin may have a protective role in inflammatory 
lung disease such as asthma but not in patients with 
COPD [29]. Several studies investigated adiponectin 
levels in CF, with inconsistent results. In adult CF serum 
adiponectin concentrations were higher than in healthy 
subjects, especially in patients with normal nutrition 
and in patients with liver disease [5, 30]. In one study 
the lowest adiponectin concentration among young 
malnourished patients was shown [5] similarly to our 
study. In other study any alteration in adiponectin le-
vels despite insulin resistance, glucose intolerance and 
subclinical chronic inflammation was detected [31–33]. 
We did not observe any correlation between an-
thropometric parameters, BMI, BMI-SDS and lung 
function and adiponectin levels. On the other hand 
adiponectin concentration was negatively correlated 
with age of children. The discrepancy between studies 
could be related to different age, stage of disease and 
organ involvement, nutritional status, metabolic distur-
bance. Additionally above mentioned authors did not 
adjust results to BMI or to free fat mass to diminished 
the potential bias.
In our previous study we demonstrated that serum 
levels of another adipokine i.e. APE-12 and APE-12/BMI 
ratio are increased in asthmatic children, particularly in 
girls [25]. In our CF patients with relative malnutrition 
serum apelin concentrations were similar to controls. 
It is not surprisingly because increased apelin expres-
sion in adipose tissue could contribute to apelin plasma 
levels. It is assumed that the overproduction of apelin 
in obesity could be a protective mechanism before onset 
of an obesity-related disorder, such as hypertension or 
cardiovascular dysfunction [14, 15]. Well known pro-
inflammatory cytokine Tumor necrosis factor-alpha 
(TNF-a), that has been implicated in many aspects of 
the airway pathology in asthma [34], may act as a direct 
up-regulator of apelin expression in adipocytes in both 
obese and lean subjects.
In conclusion, a significant increase in resistin con-
centration expressed also as resistin/BMI, and resistin/
adiponectin ratios, observed in children with CF may 
suggests that this adipokine is involved in the inflam-
matory process underlying the disease and is related 
to worse spirometric parameters describing airways 
obstruction. Although this was a cross-sectional study 
with a relatively small sample size we believe that our 
data may create a pilot knowledge for further stud-
ies evaluating the possible role of adipokines in CF 
pathogenesis. 
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